Abstract
The structures of the catalytic core of two HIV-1 encoded enzymes play a crucial role in the retroviral cycle: integrase and RNase H exhibit striking similarities. These enzymes also share a similar mechanism of catalysis. The homologies between RNase H and integrase led to studying the effect of the RNase H inhibitors on integrase. ODNs aptamers active on RNase H were shown to be strong IN inhibitors. On the contrary, compounds from the diketo acid family were previously known as integrase inhibitors. One compound of this family is able to inhibit the RNase H activity, but has no effect on integrase. Cellular topoisomerase 1 also shares a mechanism similar to that of HIV-1 integrase and RNase H. It has been reported to be present in retroviral particles and to enhance cDNA synthesis. Some topoisomerase inhibitors have been shown to be active on integrase. Moreover, topoisomerase, integrase and RNase H are inhibited by G-rich oligonucleotides. A G-quartet structure is necessary for integrase, but not for topoisomerase inhibition. This suggests that prototype structures can be exploited to develop inhibitors of two related enzymes, such as the RNase H and integrase activities of HIV-1 RT.
Keywords: hiv-1 replication, polynucleotidyltransferase family, integrase, rnase h, topoisomerase, cross-inhibition
Current Pharmaceutical Design
Title: Closely Related Antiretroviral Agents as Inhibitors of Two HIV-1 Enzymes, Ribonuclease H and Integrase: “Killing Two Birds with One Stone”
Volume: 10 Issue: 30
Author(s): Marie-Line Andreola
Affiliation:
Keywords: hiv-1 replication, polynucleotidyltransferase family, integrase, rnase h, topoisomerase, cross-inhibition
Abstract: The structures of the catalytic core of two HIV-1 encoded enzymes play a crucial role in the retroviral cycle: integrase and RNase H exhibit striking similarities. These enzymes also share a similar mechanism of catalysis. The homologies between RNase H and integrase led to studying the effect of the RNase H inhibitors on integrase. ODNs aptamers active on RNase H were shown to be strong IN inhibitors. On the contrary, compounds from the diketo acid family were previously known as integrase inhibitors. One compound of this family is able to inhibit the RNase H activity, but has no effect on integrase. Cellular topoisomerase 1 also shares a mechanism similar to that of HIV-1 integrase and RNase H. It has been reported to be present in retroviral particles and to enhance cDNA synthesis. Some topoisomerase inhibitors have been shown to be active on integrase. Moreover, topoisomerase, integrase and RNase H are inhibited by G-rich oligonucleotides. A G-quartet structure is necessary for integrase, but not for topoisomerase inhibition. This suggests that prototype structures can be exploited to develop inhibitors of two related enzymes, such as the RNase H and integrase activities of HIV-1 RT.
Export Options
About this article
Cite this article as:
Andreola Marie-Line, Closely Related Antiretroviral Agents as Inhibitors of Two HIV-1 Enzymes, Ribonuclease H and Integrase: “Killing Two Birds with One Stone”, Current Pharmaceutical Design 2004; 10 (30) . https://dx.doi.org/10.2174/1381612043382648
DOI https://dx.doi.org/10.2174/1381612043382648 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mesenchymal Stem Cells: Use in Cartilage Repair
Current Rheumatology Reviews Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adaptative and Developmental Responses to Stress in Aspergillus nidulans
Current Protein & Peptide Science Autophagy Fails to Alter Withaferin A-Mediated Lethality in Human Breast Cancer Cells
Current Cancer Drug Targets Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review
Current Medicinal Chemistry Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Current Drug Metabolism 4-Oxa-1-azabicyclo[3.2.0]heptan-7-one Derivatives as Anti-Tumor Agents
Current Medicinal Chemistry - Anti-Cancer Agents Lymphatics and Inflammation
Current Medicinal Chemistry Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Current Cancer Drug Targets Src Inhibitors as Potential Therapeutic Agents for Human Cancers
Mini-Reviews in Medicinal Chemistry An Analysis of Structure-function Co-relation between GLI Oncoprotein and HLA Immune-gene Transcriptional Regulation through Molecular Docking
Current Cancer Therapy Reviews Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Bioactive Secondary Metabolites from Endophytic Fungi
Current Medicinal Chemistry Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Lynch Syndrome Identification in Endometrial Cancer Patients: Should Universal Screening be Used for all Histologies?
Current Women`s Health Reviews Polyphenols Counteract Tumor Cell Chemoresistance Conferred by Multidrug Resistance Proteins
Anti-Cancer Agents in Medicinal Chemistry